araag2/HINT huggingface dataset:
Clinical trial NCT00606138 (phase 1/phase 2, status: completed)
Conditions: proliferative diabetic retinopathy
ICD codes: H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, E13.3553
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age 18 years or older

        Patient related considerations:

          -  Patients with Diabetes Mellitus (Type I or II) are eligible. HgA1c will be evaluated
             at the beginning of the study, but this value will have no significance in inclusion
             or exclusion.

          -  Patients will not be pregnant at enrollment and must provide evidence of the use of
             two types of birth control while enrolled in the study.

          -  Patients will have no known sensitivity to ranibizumab or other anti-VEGF injections.

        Disease related considerations:

          -  Patients will have diabetic neovascularization as seen on fluorescein angiography that
             was previously treated with full (at least 1200 laser burns) panretinal
             photocoagulation and that has persisted at least three months.

          -  There will be no evidence of ocular inflammation at enrollment.

          -  There is no restriction on patient's current medications or concomitant illnesses as
             long as there is no interference with patient follow-up.

        Other considerations:

          -  Patients may not be enrolled in another clinical study or observational trial.

          -  There is no limitation on patient's institutional status as long as the patient is
             able to participate in follow-up.

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test)

          -  Uncontrolled glaucoma on three medicines or more to control intraocular pressure

          -  Prior enrollment in the study

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial
Clinical trial NCT00505843 (phase 1, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: mk0657, comparator: placebo (unspecified), comparator: levodopa, comparator: carbidopa
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Parkinson's Disease patients between the ages of 40 and 80 inclusive

          -  Patient is in general good health based on screening assessments

          -  Patient is willing to discontinue anti-parkinson's medications at least 8 hours prior
             to dosing

          -  Patient is levodopa responsive with levodopa-induced peak-dose dyskinesias

          -  Patient taking selective serotonin inhibitors (SSRIs), sleep medications and
             neuroleptics, have been on a stable dose for at least 30 days and has not experienced
             any CNS-related side effects

          -  Patient is not a heavy smoker or drinker

        Exclusion Criteria:

          -  Patient has atypical Parkinson's syndrome due to drugs, identified metabolic and/or
             neurologic disorders, encephalitis, or other degenerative syndrome

          -  Patient has known intolerance or hypersensitivity to levodopa or carbidopa

          -  Patient has been on anticholinergics or memantine within 30 days prior to dosing

          -  Patients have a history of the following: seizure disorder, stroke or head trauma,
             pronounced cognitive impairment, psychiatric disorder, cardiovascular disease, cancer,
             diabetes as defined by HbA1c of greater than 8%

          -  Patient has a systolic BP or less than 80 mm Hg or greater than 150 mm Hg
Clinical trial NCT00506922 (phase 1/phase 2, status: completed)
Conditions: leukemia, lymphoma
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pentostatin, tacrolimus, methotrexate
SMILES: OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients receiving allogeneic hematopoietic transplants from an unrelated donor or one
             antigen mismatched related donors.

          2. Patients with AML, ALL, Hodgkin's disease, MDS (including CMML), CML in late chronic
             or accelerated phase or in blast crisis, and lymphoma in first or later relapses.

          3. Patients must have bilirubin < 1.5 mg/dL, DLCO > 50% predicted, LVEF > 45% and
             performance status 0 or 1.

          4. Candidates must have a creatinine level < 1.5 mg/dL or a calculated creatinine
             clearance > 60 ml/min.

        Exclusion Criteria:

          1. HIV seropositivity

          2. Uncontrolled infection

          3. Pregnancy

          4. Candidates should not have received chemotherapy other than hydroxyurea or Gleevec for
             at least 3 weeks prior to treatment. Maintenance therapy with oral chemotherapy is
             acceptable. Treatment day is defined as transplant day +8, which is the date of first
             dose of pentostatin.

          5. Diagnosis of myelofibrosis.
Clinical trial NCT00506064 (phase 1, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: melatonin, placebo
SMILES: COC1=CC2=C(NC=C2CCNC(C)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    terminated due to low accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Breast cancer patients having a unilateral segmental mastectomy, with or without
             intraoperative lymph node mapping, sentinel node biopsy, and axillary node dissection

          2. Ages >= 40 years

          3. American Society of Anesthesiology (ASA) physical status classification of
             preoperative functioning) 1-4 levels are acceptable

          4. Willing and able to give written informed consent

          5. Willing and able to complete questionnaires

          6. Not currently taking benzodiazepine medication for insomnia.

        Exclusion Criteria:

          1. Autoimmune diseases: rheumatoid arthritis, systemic lupus, or other collagen vascular
             disease

          2. Alcoholics

          3. Seizure disorder

          4. Thyroid disease

          5. Pregnant or lactating patients (effects not known in pregnancy)

          6. Renal/hepatic failure (if ood urea nitrogen (BUN) or creatinine (Cr) >2.5* Upper limit
             of normal (ULN); Bili or aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT)>2.5* ULN)

          7. Dementia/poor compliance

          8. Manic/psychotic patients

          9. Children/adults under 40 yrs

         10. Movement disorders (ex. restless leg syndrome)

         11. Tremor disorder (ex. parkinsonism)

         12. Chronic benzodiazepine use for sleep (>4 times per week )

         13. Designated preop medications including melatonin for sleep
Clinical trial NCT01094704 (phase 1, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: sodium chloride (7%)
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Gender: Male or female (non-pregnant, non-lactating)

          -  Cystic fibrosis documented by a compatible clinical and radiographic presentation, and
             sweat chloride > 60 mEq/l or 2 disease causing CFTR mutations.

          -  Severity of Disease:

               1. Must have FEV1 of greater than or equal to 50% of predicted at the screening
                  visit.

               2. Must have an oxygen saturation of >92% on room air as determined by pulse
                  oximetry at the screening visit.

          -  Patient or legally authorized representative agrees to the patient/individual's
             participation in the study by signing and dating the informed consent form after the
             nature of the study has been fully explained and all questions have been
             satisfactorily answered.

        Exclusion Criteria:

          -  Unstable lung disease: As defined by a change in medical regimen during the preceding
             2 weeks; an FEV1 >15% below recent (within 6 months) clinical measurements; or a
             significant new finding on chest radiograph (pneumothorax, lobar/segmental collapse)
             not considered a part of the usual, chronic progression of CF lung disease.

          -  Patients unable or unwilling to be withdrawn from hypertonic saline therapy, dornase
             alfa, or N-acetylcysteine 3 days prior to and for the duration of each Baseline and
             Treatment Period will be excluded.

          -  Patients unable to withhold use of long-acting bronchodilators (i.e., Salmeterol,
             Advair, Formoterol), anti-cholinergics, and vest therapy 12 hours prior to and for the
             duration of each treatment period.

          -  Patients unable to withhold short-acting bronchodilator 6 hours prior to and for the
             duration of each treatment period except as prescribed by the study protocol.

          -  Patients that have received an investigational drug or therapy during the preceding 30
             days.

          -  Patients that have had radiation exposure within the past year that would cause them
             to exceed Federal Regulations by participating in this study.
Clinical trial NCT00301067 (phase 1/phase 2, status: completed)
Conditions: metastatic melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed malignant melanoma

               -  Any primary tumor site

          -  Stage IV disease

               -  CNS metastases allowed

          -  Measurable disease, defined as at least 1 lesion that can be accurately measured in at
             least 1 dimension as ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan

          -  Must have had at least 1 prior systemic therapy

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

               -  Patients with no prior systemic therapy are eligible provided they are not
                  candidates for high-dose interleukin-2

          -  Recovered from all toxic effects of prior therapy

          -  More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or
             immunotherapy

          -  More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or
             immunotherapy

          -  Fertile patients must use effective contraception

        Exclusion Criteria:

          -  Life expectancy less than 4 months

          -  known HIV positivity

          -  evidence of active infection requiring antibiotic therapy

          -  other malignancy within the past 5 years except surgically resected basal cell or
             squamous cell skin cancer

          -  significant medical disease which, in the opinion of the investigator, may interfere
             with study completion

          -  pregnant or nursing

          -  Negative pregnancy test

          -  prior temozolomide or dacarbazine

          -  investigational agent within 4 weeks prior to study entry

          -  concurrent magnesium-containing antacids, digitalis, bile-resin binding drugs, or
             calcium supplements
Clinical trial NCT01134549 (phase 1, status: completed)
Conditions: hyperparathyroidism, secondary
ICD codes: E21.1, N25.81
Drugs: etelcalcetide, placebo
SMILES: C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male between 18 and 45 years of age who have provided written informed consent

          -  Subject is judged to be in good health based on medical history, physical examination,
             and routine laboratory tests

        Exclusion Criteria:

          -  History or presence of any significant acute or chronic illness (e.g., cardiovascular,
             pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic,
             dermatologic, or neurologic disease) according to the investigator

          -  History of any ongoing medical condition requiring treatment with prescription
             medication

          -  History of asthma, severe allergies including skin reactions or prior anaphylactic
             type reactions

          -  Clinically significant abnormalities on screening clinical examination or laboratory
             safety tests

          -  History of drug or alcohol abuse
Clinical trial NCT01018836 (phase 1, status: terminated)
Conditions: metastatic cancer, unspecified adult solid tumor, protocol specific
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: riluzole
SMILES: NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed solid tumor

          -  Has ≥ 2 brain metastases as demonstrated by baseline MRI

               -  Patients with only 1 metastasis are eligible provided the metastasis is too large
                  for radiosurgery and not amenable to surgical resection

          -  Not being considered for surgical resection

          -  Eligible to undergo whole-brain radiotherapy (WBRT)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  ANC ≥ 1,000/μL

          -  Platelet count ≥ 50,000/μL

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST/ALT ≤ 1.5 times ULN

          -  INR ≤ 1.5 times ULN

          -  Sodium normal

          -  Thyroid-stimulating hormone normal

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception before, during, and for ≥ 6 months
             after completion of study treatment

          -  No headaches, disequilibrium, vertigo, or dizziness

          -  No known history of hepatitis B or C

          -  No concurrent serious systemic disorder (including active infection) that would
             compromise the safety of the patient or compromise the patient's ability to complete
             the study, at the discretion of the investigator

          -  No history of allergic reactions attributed to riluzole

        PRIOR CONCURRENT THERAPY:

          -  No prior WBRT

          -  At least 2 weeks since prior systemic chemotherapy

          -  No systemic chemotherapy during and for ≥ 3 weeks after completion of WBRT

          -  Radiosurgical boosts to ≤ 3 metastases allowed, based on the discretion of the
             treating radiation oncologist
Clinical trial NCT00516451 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bms-690514
SMILES: COC1=CC=CC(NC2=NC=NN3C=CC(CN4CC[C@@H](N)[C@H](O)C4)=C23)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with advanced or metastatic solid tumors for whom the standard of care is
             ineffective or inappropriate, with adequate kidney, liver and cardiac function.
Clinical trial NCT00682929 (phase 1/phase 2, status: terminated)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: inhaled cannabis, oral thc, oral placebo, inhaled placebo
SMILES: CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1, [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1, CCCCCNC(=O)C1=COC(=N1)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1CC1=CC=CC=C1CCC(O)=O, CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    unable to complete subject recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of clinically definite multiple sclerosis as defined by Poser criteria

          -  Moderate or severe spasticity

          -  Age 21 or older

          -  Must live close to the Sacramento, CA area

        Exclusion Criteria:

          -  Preexisting pulmonary conditions, including poorly controlled asthma, chronic
             bronchitis, emphysema, bronchiectasis, and other significant pulmonary disorders

          -  Preexisting cardiac conditions, including ischemic heart disease, congestive heart
             failure, and other significant cardiac disorders

          -  Inability to abstain from tobacco or marijuana smoking, or use of alcohol or sedative
             or hypnotic medications during the duration of the study

          -  Pre-existing dementia, mania, depression or schizophrenia or other poorly controlled
             psychiatric illness

          -  Past history of abuse of recreational drugs, including marijuana and alcohol in the
             last 12 months

          -  History of or currently meets DSM-IV criteria for dependence on cannabis

          -  Use of cannabis, marijuana, or THC in the last four weeks

          -  Preexisting dementia, mania, depression, or schizophrenia or other poorly controlled
             psychiatric illness

          -  Exacerbation of MS within 30 days prior to screening visit

          -  Current use of cyclophosphamide, mitoxantrone, or cladribine

          -  Arthritis, bony and soft tissue disorders interfering with spasticity measures

          -  Inability to provide informed consent

          -  Recent cannabis use of more than twice per week one month prior to study entry

          -  For females of child bearing potential, inability to comply with adequate
             contraception
Clinical trial NCT01130142 (phase 1/phase 2, status: completed)
Conditions: metastatic pancreatic cancer
ICD codes: C25.3
Drugs: ipi-926 plus gemcitabine, placebo plus gemcitabine
SMILES: C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC[C@@H]4C[C@@H](CC[C@]4(C)[C@H]3CC2=C(C)C1)NS(C)(=O)=O, C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC[C@@H]4C[C@@H](CC[C@]4(C)[C@H]3CC2=C(C)C1)NS(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age

          -  Pathologically confirmed metastatic pancreatic adenocarcinoma

          -  At least 1 radiologically evaluable metastatic lesion (RECIST 1.1).

          -  ECOG 0 or 1

          -  Life expectancy ≥3 months.

          -  All women of child bearing potential, all sexually active male patients, and partners
             of patients must agree to use adequate methods of birth control

          -  Ability to adhere to the study visit schedule

          -  Voluntarily signed an informed consent form

        Exclusion Criteria:

          -  Islet cell, acinar cell carcinoma, non-adenocarcinoma, (i.e., lymphoma, sarcoma),
             adenocarcinoma originated from biliary tree or cystadenocarcinoma

          -  Prior treatment with chemotherapy for pancreatic cancer.

          -  Known central nervous system metastases

          -  Inadequate hematologic function

          -  Inadequate hepatic function

          -  Inadequate renal function

          -  External (percutaneous) biliary drain

          -  History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia
             requiring medication or mechanical control within the last 6 months.

          -  Venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis)
             requiring anticoagulation not appropriately anticoagulated or have NCI CTCAE Grade 2
             or greater bleeding episode in the 3 weeks prior to administration of IPI-926

          -  Concurrent administration of the medications or foods known to inhibit CYP3A activity
             to a clinically relevant degree

          -  Presence of active infection or systemic use of antibiotics within 72 hours of
             treatment

          -  Significant co-morbid condition or disease which in the judgment of the Investigator
             would place the patient at undue risk or interfere with the study.

          -  Known human immunodeficiency virus (HIV) positivity

          -  Known hypersensitivity to gemcitabine, IPI-926, or their excipients

          -  Pregnant or lactating women
Clinical trial NCT01221545 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: azd1656, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures.

          -  Male, T2DM patients aged 20-60 years

          -  Treatment with 1 to 2 OADs as Therapy for T2DM for at least 30 days prior to
             enrollment

          -  Patients should not have been treated with glitazones within 6 months prior to
             enrollment

          -  Male T2DM patients without known cardiovascular disease, with the exception of Grade 1
             hypertension without secondary organ involvement (eg. grade 1 HT is allowed if no eye,
             kidney disease or LVH has been documented).

        Exclusion Criteria:

          -  History of ischemic heart disease , heart failure, stroke, transitory ischemic attack
             or peripheral vascular disease.

          -  Prolonged QTcF>450 msec or shortened QTcF<350 msec or family history of long QT
             syndrome.

          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting
             ECG that may interfere with the interpretation of QTc interval changes.

          -  Systolic BP>159 mmHg or diastolic BP>99 mmHg at screening and on Day-1
Clinical trial NCT00327600 (phase 1/phase 2, status: completed)
Conditions: malignant melanoma
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10
Drugs: imexon, dtic
SMILES: NC1=NC(=O)N2CC12, CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Malignant melanoma; inoperable stage III or IV disease.

          -  Able to perform the activities of daily living.

          -  A projected life expectancy of at least 4 months.

          -  If female, neither pregnant nor nursing.

          -  Willing to use contraceptives to prevent pregnancy.

          -  Blood cell counts and blood chemistries in or near normal range.

          -  Prior radiation is permitted.

          -  No other serious illnesses.

          -  No other active malignancy.

          -  No serious infections.

          -  No other current drug therapy for the cancer or steroid therapy.

        Exclusion Criteria:

          -  No prior chemotherapy for the stage III or IV disease.

          -  Brain metastases